Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs), including liraglutide and semaglutide, were originally formulated for type 2 diabetes and obesity [67]; however, they have shown significant effectiveness in MASH [11]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.